Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2022 | Remaining questions on bone marrow assessment of minimal residual disease

Radhika Bansal • 4 Jun 2022
ASCO 2022
Multiple Myeloma

Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, discusses unanswered questions regarding bone marrow assessment of minimal residual disease (MRD). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Radhika Bansal

Insights into real-world outpatient administration of axi-cel and brexu-cel in R/R NHL
1:11
Insights into real-world outpatient administration of axi-cel and brexu-cel in R/R NHL
Radhika Bansal • 14 Jun 2024
Outpatient management of CAR-T therapy in multiple myeloma and lymphoma
2:22
Outpatient management of CAR-T therapy in multiple myeloma and lymphoma
Radhika Bansal • 9 Dec 2023
Outpatient management of patients with multiple myeloma treated with bispecific antibodies
1:49
Outpatient management of patients with multiple myeloma treated with bispecific antibodies
Radhika Bansal • 9 Dec 2023
Prognostic tool to identify CAR-T outcomes in patients with aggressive lymphoma
2:00
Prognostic tool to identify CAR-T outcomes in patients with aggressive lymphoma
Radhika Bansal • 11 Dec 2022

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Radhika Bansal • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Radhika Bansal • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Radhika Bansal • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Radhika Bansal • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals